
Implementation Notes (version 1.0) describing important changes to 2 of the measures included in this article are available on the American College of Cardiology (cardiosource.org) and American Heart Association, Inc. (my.americanheart.org) Web sites. The revisions detailed in “Implementation Notes 1.0 for the ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults With Nonvalvular Atrial Fibrillation or Atrial Flutter” are meant to clarify the measures and were agreed on as part of the review process for endorsement by the National Quality Forum’s Cardiovascular Endorsement and Maintenance Steering Committee.

In general, the revisions are intended 1) to clarify that the CHADS2 (Cardiac Failure, Hypertension, Age, Diabetes, Stroke [Doubled]) risk classification scheme was used in constructing these measures and 2) to acknowledge newer U.S. Food and Drug Administration–approved oral anticoagulant drugs (other than warfarin) that are now available to prevent thromboembolism in patients with atrial fibrillation.

“Measure 1. Assessment of Thromboembolic Risk Factors” (Appendix C, p. 876) and “Measure 2. Chronic Anticoagulation Therapy” (Appendix C, p. 878) should be replaced by the revised measure specifications in the online Implementation Notes 1.0, which are available at: http://www.cardiosource.org/Science-And-Quality/Practice-Guidelines-and-Quality-Standards.aspx.

http://dx.doi.org/10.1016/j.jacc.2012.06.010